drug innovation/development

ABLi Therapeutics, Inc. develops innovative treatments for Parkinson's disease and other neurodegenerative disorders by targeting non-receptor Abelson Tyrosine Kinases (Abl kinases or c-Abl) with small molecule inhibitors. Its proprietary Re-engineering Approach with Metabolism Preserved (RAMP™) drug innovation engine uses clinically validated kinase inhibitor data to design novel product candidates with enhanced brain penetration, potentially higher potency and improved safety.

Read more

kinase inhibitor engineeringsmall molecule inhibitor development